Providence Saint Joseph Medical Center—a nationally recognized, 383-bed, not-for-profit hospital in Burbank, California— has announced that it has adopted Perimeter Medical Imaging AI’s (TSXV: PINK; OTCQX: PYNKF) current S-Series OCT (optical coherence tomography) technology for high-resolution visualization of tissue microstructures during surgery.
The newly acquired (S-Series) OCT uses light to create cross-sectional 3D images of tissue microstructures at 10 times the resolution of ultrasound and X-ray and 100 times the power of magnetic resonance imaging. This resolution, combined with an imaging depth of 2 mm, is ideal for evaluation of tumor margins.
For example, in the case of breast cancer, breast tumors cannot always be seen or felt, leaving surgeons to rely on pathology after surgery to definitively determine whether all diseased tissue has been removed. This can mean waiting up to 10 days for lab results to show whether cancer remains and another surgery is required.
In a statement, Dr. Nicketti Handy, a breast surgical oncologist at Providence Saint Joseph’s Roy and Patricia Disney Family Cancer Center, commented, “With the addition of ultra-high-resolution imaging in the operating room, I can gain further intraoperative insight about margin status to help guide my surgical resection of breast cancer. If I can look at what I’ve removed and see disease at the cellular level, I can better understand if I’ve taken enough breast tissue or need to remove more. That gives me—and my patient —peace of mind.”
While formal surgical pathology evaluation remains critical for final confirmation, new technologies such as (S-Series) OCT offer valuable information in real-time to assess tumor margins and help surgeons make informed, immediate decisions.
Dr. Handy added, “Additional surgeries can take an incredible emotional toll on patients. We want to use all the tools available at the time of their operation to minimize the need for further surgery.”
In March 2025, Perimeter submitted a Premarket Approval (PMA) application to FDA for the company’s next-generation Perimeter B-Series OCT system, which combines proprietary AI technology with OCT, for use during breast-conserving surgeries in the United States. In its second quarter 2025 financial results press release, Perimeter noted that is was continuing to work closely with the FDA as the Agency continues its substantive review of the PMA application.
